Introduction
============

Age-related macular degeneration (AMD) is a complex ocular disorder affecting a critical region of the retina known as the macula, which is crucial for central vision and perception of fine detail. The disease is the primary cause of irreversible blindness in societies with demographics favouring increasing age. The aetiology of this degenerative disorder is poorly understood, but contains both genetic as well as environmental risk factors.^[@bib1],\ [@bib2],\ [@bib3]^ Central to degenerative pathology is the loss of visual function, which is associated with atrophy of photoreceptors and the underlying retinal pigment epithelium (RPE) that forms the blood--retinal barrier.^[@bib4],\ [@bib5]^ Retinal ganglion cells (RGC) and the RPE monolayer were recently identified as a major source of amyloid beta (A*β*) synthesis and secretion in the posterior eye.^[@bib6]^ A*β* is a remarkably penetrative and highly toxic protein that aggressively targets neurons and is a key feature of neurodegenerative disease.^[@bib7],\ [@bib8]^ In the eye, multiple A*β* reservoirs were discovered in the retinal environment, while elevated A*β* levels were found in the ageing retina and linked with key stages of AMD progression.^[@bib6]^ These findings support the hypothesis that A*β* has a crucial though previously uncharacterised role in driving degenerative processes in the ageing macula.

Here, we bring together the most recent findings emerging from the literature investigating AMD, neurodegeneration, as well as A*β*-structural biology, which support our hypothesis, and offer insights into fundamental degenerative events that could impair the senescent retina. A better understanding of how A*β* might target the retinal function may help in designing novel therapies to treat AMD in the future.

Age-related macular degeneration
================================

AMD is the most common cause of irreversible blindness in ageing societies, globally affecting \~50 million individuals with the direct cost estimated at nearly US\$ 255 billion.^[@bib9]^ The disease affects \~3% of adults,^[@bib10]^ and notably increases to a quarter of the population by the eighth decade of life.^[@bib11]^ A key process in vision loss is the gradual impairment of the RPE monolayer, which maintains photoreceptors on its apical surface and basally preserves the blood--retinal barrier.^[@bib1]^ Early AMD is often asymptomatic, but is typified by the presence of sub-RPE deposits known as drusen consisting of cellular debris and lipids (including extracellular matrix constituents and inflammatory components).^[@bib12],\ [@bib13]^ Formation of hard drusen, which typically occur in the peripheral retina has well-defined borders, and is regarded to be a normal part of the ageing process. In contrast, the formation of macular soft drusen that is characterised by larger size, a diffuse nature with poorly-defined borders that rarely occurs before the age of 55 years is the first clinical indicator of increased risk of disease susceptibility.^[@bib5]^ Late AMD is characterised by loss of central vision due to significant RPE/photoreceptor atrophy, referred to as 'dry AMD\', and/or the breakthrough of invasive blood vessels through the blood--retinal barrier referred to as 'wet AMD\'. Currently, the more prevalent dry form of the disease is untreatable, while several clinical strategies are used to treat the less common but more aggressive wet AMD, with varying degrees of success.^[@bib4]^

Although AMD has been characterised clinically, the underlying mechanisms, especially during early disease, remain incompletely understood. The lack of molecular characterisation between dry and wet AMD has therefore limited our understanding and definition of the disease to largely clinical observations and terminology. The recent discovery of A*β* in the ageing retina and its link with AMD presents an exciting opportunity to view AMD from a new perspective, and to better understand disease onset and progression in novel molecular terms.

A*β*---prevalence, structure, and dynamic assembly
==================================================

The amyloid precursor protein (*APP*) gene located on chromosome 21q21 encodes a ubiquitously expressed integral type I membrane glycoprotein in several alternatively spliced forms, of which the most predominate isoforms include APP^751^, APP^770^, and APP^695^. APP transcripts and proteins are reported to be abundantly expressed in mouse, rat, as well as human RGC and RPE cells,^[@bib14],\ [@bib15]^ with APP^695^ being the principal isoform expressed in the brain.^[@bib16]^ The function(s) of APP remain incompletely understood, with most studies suggesting signalling via several pathways in the brain.^[@bib17]^ The proteolytic processing of APP occurs via two mutually exclusive routes referred to as the amyloidogenic and non-amyloidogenic (or constitutive) pathway.^[@bib18],\ [@bib19]^ Successive cleavage of APP in the amyloidogenic route by enzymes *β-* and *γ*-secretase produces the monomeric A*β* peptide with a molecular weight of \~4 kDa.^[@bib8],\ [@bib20]^ However, mutations in genes encoding APP and the enzyme presenilin, a component of the *γ*-secretase complex, promotes the generation of a longer isoform of A*β* that favours the amyloidogenic pathway, and is associated with several degenerative disease of the brain.^[@bib7],\ [@bib21],\ [@bib22]^ A large body of work has focused on characterising the C-terminal cleavage of APP by *γ*-secretase that creates a heterogeneous mixture of A*β* peptides with different solubility, stability, and biological properties.^[@bib7],\ [@bib8],\ [@bib20]^ Additional heterogeneity of A*β* peptides is generated by post-translational modifications mediated by aminopeptidases, glutaminyl-cyclase/isomerases, and by phosphorylation reactions resulting in a mixture of more than 20 A*β* species,^[@bib23],\ [@bib24]^ of which A*β*~37~, A*β*~38~, A*β*~40~, A*β*~42~, and A*β*~43~ have been reported in conditioned media of cells and in body fluids.^[@bib8]^ The predominant forms of A*β* peptide are those with 40 and 42 residues, where A*β*~42~ generally forms fibrils more rapidly compared with the 40-residue species. This is considered to be due to the additional hydrophobic isoleucine and alanine residues at positions 41 and 42 in the peptide. Experimental substitution of these key amino acids with hydrophilic residues results in a decrease in assembly kinetics.^[@bib25]^ Furthermore, hydrophobic regions of A*β*~42~ spanning residues 17--21 and 31--42 are considered to be important for fibril structure,^[@bib26]^ while changes in the hydrophobicity in the sequence, for example, in the variant Phe20Glu alters A*β*~42~ toxicity, as well as the capacity to aggregate.^[@bib27]^ Soluble, monomeric A*β* can be composed of *α*-helical and/or unordered structure, which then self-associates into low-molecular weight dimers, trimers, and oligomers with a conformational change to *β*-sheet. Further conformational changes result in the formation of higher ordered structures such as protofibrils and mature amyloid fibrils with a cross-*β* structural core^[@bib28]^ ([Figure 1](#fig1){ref-type="fig"}). This sequence of events is described by the 'nucleation-dependent polymerisation model\', which proposes a 2-step process, where monomeric A*β* undergoes a slow thermodynamically unfavourable reaction to form oligomeric nuclei, followed by a rapid elongation/growth phase with the assembly of larger aggregates and fibril elongation. The formation of nuclei is the critical rate-limiting step, where further fibril formation can be significantly accelerated by the availability of preformed oligomers/nuclei.^[@bib29]^ As the nucleus is the highest energy species in this reaction, its concentration should be very low during the aggregation time-course in contrast to monomers and fibrils. However, many studies show oligomer formation in the absence of detectable amyloid fibril formation early in the A*β* amyloidogenesis time course.^[@bib30],\ [@bib31]^ This has resulted in a mechanistic revision of the original model, and polymerisation of A*β* is proposed to occur via metastable intermediaries in a process referred to as 'nucleated conformational conversion\'.^[@bib32]^

Studies utilising oligomeric A*β*, which impairs neurotransmission and causes neuronal death,^[@bib33]^ as well as a close link between soluble A*β* oligomer levels and disease progression,^[@bib34],\ [@bib35]^ has resulted in a fundamental shift of interest from fibrillar A*β* to oligomeric A*β.*^[@bib8]^ This shift in focus was highlighted in experiments utilising biomimetic unilamellar vesicles, which showed that as A*β* assembles from an oligomeric to fibrillar state, its ability to penetrate membranes also diminishes.^[@bib36]^ Even relative to the monomeric form, oligomeric A*β* was found to preferentially interact with cellular membranes to become immobilised on the cell surface.^[@bib37]^ The significant differences between oligomeric *vs* fibrillar A*β* has been proposed to be due to their different capacities to access intracellular compartments.^[@bib38]^ This does not, however, automatically imply that fibrillar A*β* plaques are benign, as studies using AD mouse models show neurons in the vicinity of plaques to have reduced synaptic density, loss of synapses, as well as elevated resting Ca^2+^ levels.^[@bib39]^ One hypothesis considers plaques as inert sinks; consisting of aberrantly folded proteins, lipids, and free metals, where a dynamic equilibrium between toxic A*β* oligomers and inert fibrils might exist, resulting in a local spillover of cytotoxic A*β* species in the vicinity.^[@bib8]^ Consequently, age-related accumulation of such A*β* deposits may be viewed as potentially pathogenic reservoirs at critical locations in the retina and brain, which may contribute to chronic 'local\' A*β*-mediated toxicity, as well as associated inflammatory events characteristic of such degenerative tissues.

Mechanisms of A*β* action in degenerative neurons
=================================================

A*β* pathology in the ageing retina is not well understood. However, insights into A*β*-mediated mechanisms may be gleaned from studying degenerative brains where some mechanistic insights and pathways have been proposed with oligomeric A*β* as a key driver of pathogenicity. Commonly cited arguments against the role of A*β* in AD includes the lack of a correlation between A*β* plaques in AD brains and the extent of cognitive decline in Alzheimer\'s patients, as well as the observation that alterations to A*β* metabolism and appearance of amyloid plaques often occur many years before clinical symptoms.^[@bib40]^ Nonetheless, degenerative neurons show a strong correlation with A*β*, a long-standing observation that is supported by a significant body of literature.^[@bib7],\ [@bib8],\ [@bib20],\ [@bib23],\ [@bib41],\ [@bib42]^ A*β* involvement in neurodegenerative and neurological spectrum disorders has been shown in Alzheimer\'s disease, Fragile X syndrome, Downs syndrome, Autism, Huntington\'s, and Parkinson\'s diseases.^[@bib7],\ [@bib43]^ AD brains, for example, are characterised by a marked neuronal loss and deposition of extracellular fibrils in neuritic plaques consisting of A*β* fibrils.^[@bib7],\ [@bib20],\ [@bib41]^ The plethora of evidence is highly supportive, but does not prove the hypothesis that ill-defined soluble A*β* species are involved upstream in the pathogenic sequence of events that cause AD.^[@bib7],\ [@bib8]^ Some of these criticisms may be addressed by studying soluble A*β* oligomers, which demonstrate a much closer relationship with disease progression compared with amyloid plaques.^[@bib34],\ [@bib35]^ The relative importance of oligomeric *vs* fibrillar A*β* in degenerative retinas remains to be established.

Another feature of A*β* pathogenicity in AD is a critical shift in the relative A*β*~40~:A*β*~42~ ratios towards elevated A*β*~42~ that is correlated with increased disease susceptibility.^[@bib44]^ However, A*β*-driven pathology is likely to be more complex and include both quantitative as well as qualitative changes to the spectrum of A*β* peptides.^[@bib8]^ Age-related changes to A*β*~42~ as well as post-translational modifications, including pyroglutamate modifications, may well alter seeding of plaques, or drive independent cytotoxicity. Ultimately, the transient and complex nature of A*β* assemblies is an obstacle to elucidating the 'toxic\' A*β* species and/or conformation(s) that are detrimental to cellular physiology and function. Such issues are likely to arise when investigating A*β* mechanisms in the retina. This limited understanding of how A*β* assemblies cause pathogenicity also extends to mechanism(s) associated with A*β* cytotoxicity. The amphipathic nature of A*β* oligomers has been suggested to contribute to their ability to penetrate/coat/overlie the surface of cellular membranes, or potentially act as cell-penetrating peptides, and has been extensively reviewed elsewhere.^[@bib42]^ As with most complex degenerative diseases, the impairment of cellular mechanisms is most likely to occur before appearance of senile plaques and onset of dementia. Indeed, a growing body of evidence supports the idea of early changes driven by toxic A*β* oligomers, including deterioration of long-term potentiation,^[@bib33]^ microtubule abnormalities,^[@bib45]^ as well as loss of synaptic function.^[@bib46]^ The soluble A*β* fraction is primarily composed of A*β* monomers, dimer, trimers, and SDS-stable A*β* oligomers,^[@bib34],\ [@bib44]^ some of which has been reported in hippocampal CA1 region and the cortex of ageing human brains, even in the absence of senile plaques.^[@bib47]^ The potency of these small A*β* assembles were highlighted in a study where introduction of soluble A*β* dimers and trimers into rodent brains resulted in cognitive impairment.^[@bib48]^ Central to the idea of soluble toxic A*β* peptides as a driver of early pathogenicity is the initial entry of oligomeric A*β*, possibly via disruption of membrane integrity.^[@bib36],\ [@bib49]^ Our work has recently shown that oligomeric A*β* is rapidly internalised by neurons to accumulate in clathrin-positive endosomes,^[@bib50]^ supporting evidence that clathrin-mediated endocytosis may be involved in A*β* internalisation,^[@bib51]^ as well as findings showing inhibition of endosomal activity partially reduces A*β*-mediated toxicity.^[@bib52]^ Other fundamental cellular mechanisms impaired by oligomeric A*β* in susceptible neurons are likely to include the impairment of axonal transport, mitochondrial dysfunction, and synaptic vesicle dynamics. Our ongoing studies to understand these key pathogenic changes will provide valuable insights into early A*β*-mediated activity in degenerative brains, as well as inform on potential pathways of damage in the retina.

Evidence of A*β* in the ageing retina and AMD
=============================================

Constitutive A*β* generation in the normal retina
-------------------------------------------------

Both the retina and the central nervous system (CNS) share a common origin as both are derived from the developing neural tube. Both structures interface intimately with the adjacent vasculature via the blood--retinal and blood--brain barriers. Furthermore, with increasing age, both the retina and the brain develop extracellular deposits associated with degenerative pathology, referred to as drusen and senile plaques, respectively. It is therefore unsurprising that the many striking similarities between drusen and senile plaques include A*β*. Other shared components include the following; serum amyloid P component, apolipoprotein E, immunoglobulin, basement membrane matrices, proteoglycans, and metal ions (Fe^3+^, Cu^2+^, and Zn^2+^), acute-phase reactants, proteases/clearance-related elements, and several complement proteins, as well as other inflammatory mediators that are indicative of local inflammation typically associated with sub-retinal deposits.^[@bib6]^ Such remarkable similarities between drusen and senile plaques, coincident with age and poor clinical prognosis, suggest that similar pathological mechanisms may drive degenerative changes in the retina as well as the brain.

Studies have now confirmed that RGC, the inner nuclear layer of the retina,^[@bib15],\ [@bib53]^ as well as the RPE^[@bib54]^ expresses APP, and possesses the necessary cellular machinery to generate A*β*. Retinal and RPE cells expresses *β*-secretase, the four known subunits of *γ*-secretase, and the three major APP isoforms APP^770^, APP^751^, and APP^695^, as well as neprilysin.^[@bib14],\ [@bib54],\ [@bib55]^ Furthermore, isolated RPE cells from wild-type C57BL/6 mice were shown to readily synthesise and secrete A*β*, which accumulated in conditioned media,^[@bib56]^ while A*β* expression levels increased in rat RGC with age.^[@bib15]^ This was not surprising, as abundant A*β*~40~ and A*β*~42~ peptides have been reported in both aqueous and vitreous humours. A*β* in ocular fluid is thought to originate primarily from the retina and RPE, from where it is secreted to the vitreous humour and subsequently transported to the anterior chamber.^[@bib55],\ [@bib57]^ This follows a similar pattern observed in the CNS, where A*β* is primarily synthesised in neurons but accumulate in cerebrospinal fluid (CSF).^[@bib58]^ Not only does the retina and RPE constitutively express APP,^[@bib53],\ [@bib55]^ but RPE cells overlying, flanking, or displaced by drusen also show A*β* immunoreactivity in the cytoplasm.^[@bib54],\ [@bib57]^ Current measurements suggest that A*β* levels in the bovine vitreous and retina are considerably lower compared with CSF levels,^[@bib53],\ [@bib55]^ but this may reflect the dynamic behaviour of 'local A*β* levels/species in the retina\', as well as initial problems associated with A*β* quantification in these tissues. It is noteworthy that the retina is not only continuously exposed to A*β* species, but the very high concentrations of *α*-secretase cleaved soluble APP found in the vitreous fluids is comparable only to levels in CSF.^[@bib55]^ Intriguingly, a recent study demonstrated that *α-* and *β*-secretase cleaved APP levels in conditioned media of wild-type neuronal cultures to be directly linked to extracellular A*β* concentrations, with a 1 : 1 relationship between *β*-cleavage of APP and release of A*β.*^[@bib59]^ This highlights some of the difficulties in accurately quantifying A*β*, and given what is known about its pathogenicity in degenerative brains, provides further evidence that the retina is constitutively exposed to A*β* under normal/healthy conditions.

The retinal A*β* burden increases with age
------------------------------------------

Growth of A*β* deposits with advancing age may be viewed as an alteration in the balance between increased A*β* synthesis *vs* a reduction in the ability to clear such aggregates. Either or both fates may be sufficient to elevate the A*β* burden in the ageing retina. For example, cultured RPE cells from geriatric C57BL/6 mice displayed elevated A*β* levels in conditioned media compared with RPE cells from younger controls. In contrast, mRNA levels of neprilysin (which clears A*β*) were significantly decreased, while *β*-secretase activity was elevated in senescent RPE cells, indicating the ability to clear A*β* also diminished with age.^[@bib56]^ Analysis of C57BL/6 mice as young as 3 months by immunofluorescence and immunoblotting techniques revealed A*β* accumulations in the RPE-Bruch\'s membrane interface, as well as in retinal/choroidal blood vessels. With age, A*β* accumulations in the critical RPE-Bruch\'s region increased in subsequent months.^[@bib60]^ Of note, this pattern of amyloid deposition was observed in a region where A*β* accumulation is thought to first occur in AMD; in close proximity to the inner collagenous layer of Bruch\'s membrane.^[@bib61]^ Interestingly, A*β* staining in inner retinal vessels appeared discontinuous, while A*β* positivity in the choroidal vasculature were confined to sub-groups of vessels suggesting a degree of selectivity in A*β* deposition.^[@bib60]^ Such points of vulnerability may be related to thinning of blood vessels and reduced flow rates, as observed in the retinal vasculature of early AD patients.^[@bib62]^

A*β* deposition with increasing age was not restricted to sub-RPE regions, but was unexpectedly discovered to accumulate in photoreceptor outer segments (POS) in older mice. Such deposits were identified as early as 3 months and by 12 months the outer segments were completely wrapped in A*β*-containing material, which appeared qualitatively different by 24 months.^[@bib60]^ Although there is no direct evidence that such material is purely A*β*, the close association between A*β*-immunostaining patterns and scanning EM images argue that A*β* at least constitutes an element of such age-related deposits. Additionally, intravitreal injection of oligomeric A*β*~40~ into wild-type rats produced the highest immunostaining intensity levels in POS, supporting the idea of preferential A*β* accumulation in the apical proximity of RPE cells.^[@bib63]^ Analysis of human post-mortem samples between ages of 31 and 90 years mirrored a similar pattern of increasing A*β* immunostaining in POS.^[@bib60]^ This pattern of A*β* accumulation originating at the apical tip of POS and progressing along its length illustrate-specific A*β* aggregation,^[@bib60]^ and as such, agree with other findings^[@bib14],\ [@bib54],\ [@bib55],\ [@bib56]^ showing retinal/RPE generated A*β* accumulating in posterior eye with advancing age ([Figure 2](#fig2){ref-type="fig"}).

A*β* aggregation is involved in key stages of AMD
-------------------------------------------------

The evidence discussed thus far confirms that A*β* has a central role in AMD, a large part of which is derived from human post-mortem eyes,^[@bib57],\ [@bib61],\ [@bib64]^ and provides a clinical snapshot of A*β* involvement in key stages of disease progression. Although such data are often based on high-quality static images, they nonetheless portray a tantalising picture of dynamic A*β* activity in the ageing retina. The presence of A*β* in the retina appears to be correlated with age as well as the extent of sub-retinal drusen loads. For example, EM analysis of 152 human donor eyes ranging from 9 to 91 years of age showed that A*β* assemblies were most prevalent in retinas with moderate-to-high drusen loads.^[@bib57]^ Although links between sub-RPE A*β* deposition in the macula *vs* peripheral retina, or early *vs* late AMD, or indeed with specific disease phenotypes were not examined, these findings suggest that A*β* might be associated with more advanced stages of AMD. A smaller study consisting of nine AMD retinas and an equivalent number of control retinas found that drusen containing A*β* were present only in patients with AMD. Elevated A*β* reactivity was detected in four of nine AMD retinas, with a few A*β*-positive drusen in two early AMD retinas and numerous A*β*-positive drusen in two retinal samples with geographic atrophy.^[@bib65]^ Although this study lacked sufficient sample numbers to arrive at any firm conclusions linking A*β*-positive drusen with AMD, it nonetheless suggests that A*β* pathogenicity is involved in distinct stages of AMD. Confocal immunofluorescence and ultrastructural analysis of post-mortem retinas revealed that A*β* is localised in sub-structural vesicular components within drusen referred to as 'amyloid vesicles\'.^[@bib54],\ [@bib57],\ [@bib61],\ [@bib64]^ These structures ranged from 2 to 10 *μ*m in diameter and were readily detected in both macular and peripheral drusen from donors with/without clinical AMD.^[@bib54]^ Such amyloid-containing structures within drusen have been reported by several groups using a variety of different A*β* antibodies and appear to vary between 0.25--10 *μ*m,^[@bib57]^ 10--15 *μ*m,^[@bib61]^ and 10--20 *μ*m in diameter.^[@bib64]^ In addition, the relative shapes of such amyloid structures within drusen also varied; from spheres to elongated forms,^[@bib57],\ [@bib61]^ and to vesicles that appear to be in the process of budding or fusing.^[@bib54]^ Although all studies were in agreement that each drusen may contain multiple amyloid structures, descriptions of amyloid cores and vesicles were largely defined by the choice of A*β* antibodies used in the respective studies.^[@bib54],\ [@bib57],\ [@bib61],\ [@bib64]^ Some drusen were described as densely packed with amyloid vesicles accounting for a significant proportion of their total volume, while others contained only a single large vesicle that occupied a substantial portion of the drusen mass.^[@bib54]^ For example, Anderson *et al*^[@bib57]^ reported a single drusen to contain \>100 spheres of various sizes. The presence of multiple amyloid cores in larger drusen suggested that these drusen may have formed from a coalescence of smaller drusen,^[@bib61]^ indicating the evolving complexity of A*β* containing drusen over long periods of time.

Further analysis of amyloid vesicles revealed a highly organised interior consisting of concentric ring-like layers with varying electron densities and bound by an electron dense shell of \~100 nm thick.^[@bib57]^ A similar description have also been made with the vesicle interior described as consisting of flocculent material and/or concentric ring-like elements bound by an outer shell or vesicle rim.^[@bib54]^ A*β* immunoreactivity was detected throughout all the layers, signifying the apparent central role of A*β* in amyloid vesicles within drusen.^[@bib57]^ Despite the limited scope of data offered by human post-mortem eyes along a single plane, as well as a singular point in time, they nonetheless show that A*β* antibodies specific for different conformations localise to different parts of amyloid structures.^[@bib61],\ [@bib64]^ For example, the A11 and M204 antibodies that specifically recognise the toxic oligomeric A*β* forms, but not A*β* monomers or fibrils were typically found to localise centrally within drusen in close proximity to the inner collagenous layer of Bruch\'s membrane.^[@bib61],\ [@bib64]^ Hence, the authors believe that such oligomeric cores are different to the substructures described by Anderson *et al*,^[@bib57],\ [@bib61]^ but conclude that they nonetheless form the majority of A*β* structures observed in drusen.^[@bib64]^ Additionally, a wide spectrum of antibodies such as OC, 6E10, WO1, WO2, and 4G8, which specifically bind to A*β* protofibrils and mature fibrils showed a propensity to accumulate towards the outer periphery and shell of amyloid structures within drusen.^[@bib54],\ [@bib57],\ [@bib61],\ [@bib64]^ Hence, despite the lack of a comprehensive study that systematically investigates the full spectrum of A*β* conformations in retinal substructures of human *mort-mortem* retinas, the collective findings thus far agree that drusen contain an abundant variety of A*β* forms and structures ([Figure 3](#fig3){ref-type="fig"}).

A*β* deposits in the retina triggers a pro-inflammatory and pro-angiogenic microenvironment
-------------------------------------------------------------------------------------------

The experimental exposure of cells in the retina, RPE, and choroid to A*β* can induce fundamental changes associated with local retinal inflammation. This evidence is derived from a variety of experimental culture systems, as well as from animal models including Zebra fish, rabbits, rodents, and human post-mortem eyes. A systematic review of these findings reveals a progressive pattern of A*β*-mediated inflammatory and pro-angiogenic effects in the ageing retina, in which we are able to discern between early A*β*-driven changes as well as late-stage AMD pathology associated with A*β*. Such changes are likely to be triggered, and chronically sustained, by a toxic cocktail of A*β* peptides that is readily supplied by multiple A*β* reservoirs surrounding the ageing retina, which includes the immediate environment around the RPE,^[@bib56]^ in vitreous fluid,^[@bib55],\ [@bib57]^ the coating of the outer segments of photoreceptors,^[@bib60]^ and in sub-retinal drusen.^[@bib54],\ [@bib57]^ Furthermore, these early events are likely to occur well in advance of clinical AMD and include alterations in the expression profiles of key inflammatory genes. For example, human foetal RPE cultures treated with nanomolar concentrations of oligomeric A*β*~40~ for as little as 24 h resulted in a significant upregulation of pro-inflammatory cytokines IL-1*β* and IL-8.^[@bib66]^ Another study also demonstrated IL-8 as well as MMP-9 overexpression following oligomeric A*β*~40~ treatment, coincident with RPE senescence and compromised barrier properties.^[@bib67]^ The role of IL-1*β* in generating reactive oxygen species (ROS) as well as IL-8 in RPE cells has been previously documented, while IL-8 itself is a potent inducer of chemotaxis, correlated with amplification of inflammatory responses and neovascularisation.^[@bib68],\ [@bib69]^ Exposure of the D407 RPE cell line to oligomeric A*β*~40~ resulted in elevated IL-33, which can accelerate the production of Th2-associated cytokines and promote tissue inflammation.^[@bib70]^ Elevation of oxidative stress responses in cultured ARPE-19 cells were also observed within hours of treatment using nanomolar to micromolar levels of the more toxic oligomeric A*β*~42.~^[@bib71]^ These pro-inflammatory activities driven by A*β* are not limited to cultures but are also replicated in animal models. For example, the use of wild-type rats to investigate acute effects of A*β*~40~ following intravitreal injections revealed elevated levels of pro-inflammatory IL-1*β*, IL-6, IL-8, and TNF-*α* in the RPE/choroid and neuroretina. In addition, elevation of caspase-1 and NLRP3 indicated activation of the retinal/RPE inflammasome,^[@bib63]^ which has been implicated in AMD susceptibility.^[@bib72]^ The varying fates of retinal/RPE cells following acute application of A*β in vivo* may reflect a mixture of varied A*β* cytotoxicity as well as A*β*-dosages, length of treatment as well as sites of injection. Hence, intravitreal A*β*~40~ injections failed to show significant retinal/RPE cell death,^[@bib63]^ which is in stark contrast to RPE hypopigmentation, disorganised photoreceptors/RPE, and halving of photoreceptor numbers soon after sub-retinal injections of oligomeric A*β*~42~ into wild-type mice.^[@bib71]^ Similarly, RGC cultures acutely treated with A*β*~25--35~ or A*β*~1--42~ induced apoptosis at micromolar concentrations, while treatment with A*β*~1--40~ proved less toxic.^[@bib73]^ The pattern of RGC apoptosis was also observed in a mouse model of glaucoma-associated A*β* co-localisation,^[@bib74]^ highlighting the potential involvement of A*β* in multiple degenerative conditions in the eye. Taken together, these findings demonstrate that key changes in gene expression of retinal and RPE cells mediated by A*β* are replicated *in vivo* to promote a pro-inflammatory milieu in early AMD pathogenesis.

The complement system consist of regulatory molecules in systemic circulation, which constitute the classical, alternative as well as the lectin pathways, and has an important role in AMD susceptibility and risk of disease progression.^[@bib75]^ These distinct mechanism of the complement system converge on a common terminal pathway culminating in the formation of the membrane attack complex (MAC), opsonization, and lysis of target cells as well as the recruitment and/or activation of inflammatory cells.^[@bib75],\ [@bib76]^ The ability of A*β* peptides to induce chronic inflammation in degenerative brains via direct and independent activation of the complement pathway has been well established.^[@bib77],\ [@bib78]^ Evidence now supports the possibility that A*β*, specifically around drusen, can mediate early inflammatory events in degenerative retinas in a similar manner. An insight into such mechanisms is provided by studies of human post-mortem eyes, showing RPE-synthesised factor H (HF1), a major regulator of the alternative complement pathway, co-localising with its ligand C3b/iC3b in amyloid-containing vesicles within drusen. HF1 and MAC accumulated along the surface of amyloid vesicles in the RPE-choroidal interface and were prevalent in the macular regions from donors with prior histories of AMD.^[@bib79]^ This association was also shown in another study of human post-mortem retinas, which revealed iC3b, the activated product of complement C3 in close proximity and co-localised with A*β* deposits in amyloid vesicles.^[@bib54]^ A*β* deposits in drusen may form a nucleus around which chronic 'wound-like\' events may occur ([Figure 3](#fig3){ref-type="fig"}), a model which builds on an elegant hypothesis that chronic local inflammatory and immune-mediated events at the level of the RPE-Bruch\'s membrane have a critical role in drusen biogenesis, and in the pathobiology of AMD.^[@bib13],\ [@bib54],\ [@bib76],\ [@bib79]^

The RPE has a central role in maintaining the blood--retinal barrier, an important function in sustaining the immune-privileged status and homoeostasis of the retinal environment.^[@bib1],\ [@bib5]^ A*β*-mediated pathogenicity in early AMD may also target the structural integrity of RPE barrier properties. For example, acute treatment of ARPE-19 monolayers with 0.1--10 *μ*M oligomeric A*β*~42~ resulted in the disruption of RPE junctional complexes and actin cytoskeleton, formation of actin stress fibres, impairment of trans-epithelial permeability as well as loss of cell attachment.^[@bib71]^ Similar studies in human foetal RPE cultures found that exposure to A*β*~42~ elevated MMP-9 secretion and shifted cells into a senescent state.^[@bib67]^ These findings show a systematic breakdown of ZO-1 and occludin junctional complexes within the RPE that is mediated by MMP-9, and suggest an early mechanism by which chemokine gradients can be established across barriers for subsequent migration of inflammatory cells. Such MMP-driven mechanistic changes have been previously documented in retinas of patients with AMD.^[@bib80]^ A*β*-driven structural changes in the RPE monolayer were also observed *in vivo*, following sub-retinal injections of oligomeric A*β*~42~, and consisted of disorganised actin filaments and junctional complexes in the absence of apoptosis. Further changes observed include RPE hypopigmentation, damage to photoreceptors including loss of outer segments, and shorter inner segments.^[@bib71]^ The complexities of A*β*-mediated activities also include the capacity to generate elevated ROS, a well-documented process in degenerative brains.^[@bib81]^ The retina, which is normally subject to constantly high photoxidative stresses,^[@bib82]^ may be particularly prone to A*β*-induced ROS-induced damage, in a process compounded by increasing lipofuscin accumulation within RPE cells with age. Furthermore, A*β* has been shown to induce cellular senescence and impair mitochondrial activity in RPE cells.^[@bib56],\ [@bib67],\ [@bib71]^ The substantial impact of accumulated mitochondrial damage in post-mitotic RPE cells has been well documented in AMD susceptibility.^[@bib83]^

Late-stage A*β*-driven mechanisms in AMD may be considered cumulative, and most likely to occur after decades of chronic A*β* exposure in the ageing retina. Although we do not yet fully understand the extent of these mechanisms, a numbers of studies provide a tantalising insight. For instance, exposure of human RPE cultures to 1--25 *μ*M A*β*~40~ for as little as 24 h resulted in a significant increase of pro-angiogenic VEGF (vascular endothelial growth factor) expression and a concomitant decrease in anti-angiogenic PEDF (pigment epithelium derived factor).^[@bib14]^ The role of VEGF in increasing vascular permeability and triggering endothelial cell proliferation has been well established.^[@bib1],\ [@bib5],\ [@bib14]^ The RPE monolayer appears to be the only source of VEGF in the retinal environment, and secretes several VEGF isoforms through its basolateral surface towards the choriocapillaris.^[@bib82]^ VEGF has a key role in the development of CNV, with anti-VEGF treatment currently forming the mainstay of treatment for wet AMD.^[@bib1]^ The ability of A*β* peptides to elevate VEGF levels in the vicinity of the blood--retinal barrier via direct mechanisms^[@bib14]^ and possibly via indirect inflammatory triggers^[@bib54],\ [@bib63],\ [@bib70],\ [@bib76]^ may help explain the as yet incompletely understood pathology underlying VEGF elevation preceding neovascularisation. Furthermore, conditioned media from RPE cells exposed to A*β*~40~ triggered tube formation in human umbilical vein endothelial cells, suggesting that A*β* also has the capacity to directly influence CNV.^[@bib14]^ Such direct pro-angiogenic mechanisms were further confirmed when injection of A*β*~42~ into Zebra fish eyes resulted in a significant increase of retinal capillary bed densities.^[@bib84]^ Collectively, these findings demonstrate that A*β* peptides have a central role in driving early as well as late-stage degenerative mechanisms in the ageing retina.

AMD risk factors promotes A*β* aggregation in the ageing retina
---------------------------------------------------------------

The heterogeneous nature AMD aetiology suggests that the most likely scenario involves a convergence of multiple risk factors to trigger disease pathology in the ageing retina.^[@bib1],\ [@bib5],\ [@bib85]^ One intriguing idea is that other well-characterised AMD/AD risk factors may have a supportive role in exacerbating A*β* pathology in the eye. These may include a combination of genetic as well as epigenetic risk factors such as diet. Studies to elucidate the molecular basis underlying these changes illustrate striking parallels of A*β*-mediated damage common to both retina and brain. For example, A*β*-mediated disruption of the blood--retinal barrier^[@bib71],\ [@bib80]^ is mirrored in the blood--brain barriers of Tg2576 mice. Specifically, overexpression of A*β*~42~ in these mice resulted in significant disruption of tight junctions in the cerebral vasculature, long before consolidation of amyloid plaques.^[@bib86]^ However, it must be noted that genetic risk factors driving pathology in one compartment may not necessary act in an identical manner in another location. ApoE, which encodes a glycoprotein responsible for cholesterol transport is highly expressed in the retina and is likely to have an important role in maintaining normal retinal function. The frequency of ApoE alleles (*ɛ*2, *ɛ*3, and *ɛ*4) displays a diverging story in AMD and AD. In AD, for example, the *ɛ*4 allele confers a dose-dependent elevated risk with a decrease in the mean age of AD onset. In contrast, the *ɛ*2 allele has a beneficial effect on disease-free time, and appears to impart a measure of protection.^[@bib7],\ [@bib8]^ In contrast, our studies using pooled analysis of a large data set of both published and previously unreported studies shown that *ɛ*4 protects against late AMD. We also reported an increased risk for late AMD in individuals homozygous for *ɛ*2.^[@bib87]^ Such contrasting effects may reflect significant variations in the local structure and physiologies in the senescent brain and retina, respectively. For instance, the positively charged *ɛ*4 haplotype has been proposed to improve permeability of Bruch\'s membrane, which could facilitate lipid transport and reduce sub-retinal debris accumulation associated with drusen formation.^[@bib12]^ Reduced transport of lipoprotein across Bruch\'s membrane is a consequence of ageing, and has been proposed to promote drusen deposition and impairment of the RPE.^[@bib88]^ Furthermore, the *ɛ*4 isoform has also been implicated in the transport of macular pigments lutein and zeaxanthin, the reduced dietary intake of which is associated with increased risk of AMD.^[@bib89]^ An important factor regulating ApoE effects is their interaction with A*β*. In the past, distinct binding properties of different ApoE isoforms to A*β* has been suggested to underlie the discrepancies associated with each genotype,^[@bib90]^ while more recently, ApoE isoforms were shown to affect A*β* clearance^[@bib91]^ and/or oligomerisation,^[@bib92]^ which could lead to diverging outcomes in different tissues.

Cholesterol forms a vital component of the eukaryotic cell regulating membrane fluidity, permeability, and electrical properties. Evidence supports the possibility that the cholesterol content of specific anatomically defined locations in the brain may leave some regions particularly vulnerable in old age. For example, a significant reduction of cholesterol levels in the temporal gyrus of AD brains *vs* non-demented brains could result in increased A*β* permeation. Furthermore, the decreased cholesterol/phospholipid ratio in AD brains may affect APP cleavage and elevate A*β* generation, as well as facilitate increased A*β* permeability.^[@bib42]^ Studies using mouse models have previously shown that a cholesterol enriched diet dramatically exacerbated A*β* pathology, whereas cholesterol-lowering drugs decreased the A*β* burden as well as AD pathology.^[@bib93]^ Although the precise nature of interaction(s) between cholesterol and A*β* is not fully understood,^[@bib93]^ there is evidence to suggest that cholesterol has the capacity to modulate A*β* generation and its clearance.^[@bib94]^ Similar effects were observed when RPE cells obtained from C57BL/6 mouse were treated with cholesterol resulted in a significantly increased A*β* production, while activities of A*β*-degrading enzyme neprilysin and anti-amyloidogenic *α*-secretase showed a concomitant decrease. Furthermore, senescent C57BL/6 wild-type mice fed with a cholesterol enriched diet developed sub-RPE deposits containing A*β.*^[@bib95]^ This pattern of cholesterol-driven A*β* pathology was also observed when New Zealand white rabbits were switched to a cholesterol enriched diet. A*β* deposition was detected in POS, in the outer and inner nuclear layers, as well as in RGC. This was accompanied by increased A*β*~40~ and A*β*~42~ levels in retinal samples as quantified by ELISA measurements. Further changes include drusen-like debris, increased generation of ROS and apoptotic retinal cells.^[@bib96]^ The high dietary intake of cholesterol and saturated fat has been regarded as AMD risk factors for a long time. This is coupled with the observation that cholesterol forms a major component of drusen, the ageing Bruch\'s membrane and sub-retinal lesions.^[@bib88]^ As most drusen components are thought to be primarily derived from the retinal environment,^[@bib12],\ [@bib88]^ implications for the interplay between A*β* and cholesterol is an intriguing possibility.

Animal models of AMD and anti-A*β* antibody therapy
===================================================

As an age-related degenerative disease with a complex aetiology, the full spectrum of AMD pathology has been challenging to reproduce in animal models. This, however, has not prevented the development of numerous rodent, rabbit, porcine, and non-human primate animal models. The widely utilised mouse/rat models have the benefit of lower costs, ease of maintenance and the capacity to develop disease symptoms in a relatively short time period, but suffers from defects including the most glaring of which is the lack of a macula. Critically, no single model has been successful in reproducing the full disease spectrum of AMD, although convincing models exist that reproduce limited features of both geographic and exudative forms of the disease. In contrast, the use of non-human primates offers the opportunity to study AMD in a system bearing closer resemblance and physiology to humans, but carries a number of disadvantages including considerable ethical implications, difficulties in genetic manipulation, as well as longer time scales prior to disease onset.

Recent findings that the A*β* burden considerably increases in the senescent retina, and that A*β* may have a central role in drusen formation, has revealed yet another feature that needs to be reproduced *in vivo*. As with other key milestones of disease progression, the development of an A*β* phenotype along with drusen formation, RPE/photoreceptor abnormalities, CNV, and progressive visual impairment may be critical in ultimately developing a *bona fide* model of AMD. Unfortunately, only a limited number of rodent models are currently in existence that reproduce retinal A*β* abnormalities. One of the first animal models to place A*β* in the centre stage of retinal pathology was a neprilysin-deficient senescent mouse model that developed A*β*-containing drusen, changes in the outer retina, as well as RPE abnormalities.^[@bib14]^ This model also exhibited elevated VEGF expression and diminished PEDF levels suggesting a shift into a pro-angiogenic phenotype, but surprisingly failed to develop CNV even at the advanced age of 27 months. The authors concluded that the lack of progression to late-stage AMD was likely due to the insufficient Bruch\'s membrane abnormalities, differences in the role of complement activation or that the animals were insufficiently aged to mimic the senescent human retina. Nonetheless, this mouse model represents a useful tool to study A*β*-driven pathology in early disease.^[@bib14]^

The senescent human APOE4 knock-in mouse represents another intriguing model, which upon switching to a high-fat cholesterol-rich (HFC) diet develops drusen, thickened Bruch\'s membrane, abnormal RPE adjacent to degenerative photoreceptors, and in extreme cases CNV.^[@bib97]^ Of note, A*β* deposits were associated with sub-RPE drusen and with neovascular vessels, with mice developing visual impairment as measured by electroretinogram. Although this model represents an excellent tool to investigate A*β*-mediated pathology in the mouse retina in its own right, the most pertinent finding was that a dose-dependent systemic administration of antibodies targeting the C-terminal of both A*β*~40~ and A*β*~42~ in APOE4-HFC mice resulted in a significant protective effect.^[@bib98]^ Hence, immunised age-matched animals showed reduced A*β* and activated complement components in sub-RPE deposits, improved structural integrity of the RPE monolayer as well as visual protection. This follows the pattern of reduced amyloid plaques and improved cognitive function in mouse models of AD treated with anti-A*β* antibodies.^[@bib8],\ [@bib20]^ The importance of A*β* in driving retinal degenerative events that manifest as different pathologies was also demonstrated in a mouse models of glaucoma, where A*β*-neutralising antibody treatment produced \>80% reduction in RGC apoptosis.^[@bib74]^ Collectively, such evidence firmly places A*β* at the centre stage of degenerative events in the ageing retina.

A*β* and AMD---lessons from neurodegeneration and a way forward
===============================================================

Developed societies are confronted with new challenges as the numbers of older individuals gradually begin to outstrip the younger age groups. The impact of age-related illnesses such as dementia, AMD, cardiovascular disease, and osteoporosis are felt at many levels; from individuals to families and societies, and have a major role in setting government health policy. In the UK, AMD affects a significant proportion of the elderly, as well as adults that are registered legally blind. For patients with nvAMD, anti-VEGF treatment offers scope for burdensome disease management through repeated hospital visits consisting of monthly intravitreal injections. However, not all respond to this therapy, while at present, the majority of AMD patients have no effective treatment. The complex disease aetiology of AMD poses major challenges to devising effective solutions. Recent advances in understanding the genetic architecture of AMD has yet to translate to meaningful benefits for patients. An incomplete understanding of the biological processors underpinning disease mechanisms largely accounts for this critical knowledge gap. Degenerative processes in the ageing retina and brain show striking similarities, and offers scope for identifying novel targets as well as pathogenic mechanisms. A*β*, a highly toxic and aggregate-prone peptide capable of eliciting local inflammation and involved in key stages of AMD can be considered such a candidate.

Here, we discussed the hypothesis and exciting new findings that show A*β* has the capacity to play a key role in AMD, the study of which may offer a better understanding of early disease mechanisms, as well as molecular pathways sustaining chronic retinal degeneration. Examples of shared pathology in AD patients include reduced thickness of the nerve fibre layers,^[@bib99]^ abnormal retinal blood circulation,^[@bib62]^ as well as reduced choroidal thickness,^[@bib100]^ locations where degeneration also occurs in glaucoma and AMD.^[@bib1],\ [@bib5],\ [@bib74]^ Similarities are also found between AD senile plaques and AMD drusen,^[@bib6]^ as well as the pattern of selective tissue damage, which argues for shared molecular mechanisms in at least some stages of these diseases. Studies of A*β* and associated pathology in the retina have the potential to offer new insights into AMD, and approach this debilitating blinding disease from a new perspective. Such investigations are already underway in our laboratory.
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![(a--c) Show negative stained transmission electron micrographs depicting the self-assembly of A*β*~1--42~ at pH 7.4, 50 *μ*M. (a) Shows small spherical oligomers that are visible immediately after preparation of A*β*~1-42~ peptide (Soura *et al*^[@bib50]^). These assemble further by 24 h to form (b) elongated protofibrils, and finally (c) amyloid fibrils after 48 h incubation. d Shows a structural model of an amyloid fibril composed of cross-*β* structure and showing a slow twisted architecture. Generation of the model is described in Morris *et al.*^[@bib101]^](eye2015100f1){#fig1}

![Schematic diagram showing multiple locations of A*β* synthesis, secretion, and aggregation in the ageing retina (red asterisk) that is reported in the literature to date. BrM, Bruch\'s Membrane; POS, photoreceptor outer segments; RGC, retinal ganglion cells; RPE, retinal pigment epithelium.](eye2015100f2){#fig2}

![A*β* assemblies are prevalent in individuals with moderate-to-high levels of drusen. A*β* is organised into spherical structures termed 'amyloid vesicles\', which can occupy a large portion of drusen volume, and form potential sites of complement activation. A druse may be densely packed with several amyloid vesicles or contain only a single large vesicle. The presence of distinct A*β* structures may reflect the evolving nature of drusen with disease progression. For example, the presence of multiple oligomer cores in a large drusen may be due to smaller drusen coalescing over time. A*β* in drusen correlates with degenerating photoreceptors and RPE. CC, choriocapillaris; BrM, Bruch\'s membrane; RPE, retinal pigment epithelium.](eye2015100f3){#fig3}
